UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~June~~September 2110, 2019

MEDICAL INNOVATION HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)

Colorado	000-27211	84-1469319
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

~~5805~~575 ~~State~~Pharr ~~Bridge Road~~Rd, ~~Suite~~NE ~~G-328~~#53191, ~~Duluth~~Atlanta, GA ~~30097~~30355-6000

(Address of Principal Executive Offices)

(~~866~~404) ~~883~~919-~~3793~~4838

(Registrant's Telephone Number, Including Area Code)

5805 ~~_______________________________________________~~State Bridge Road, Suite G-328, Duluth, GA 30097/(866) 883-3793

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each Class	Trading Symbol	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

~~Item~~ITEM 18.01 ~~Entry~~OTHER ~~into a Material Definitive Agreement~~EVENTS

OnAs of ~~June~~September 2110, 2019, ~~Medical Innovation Holdings, Inc. (~~the “Company”)’s ~~entered~~current ~~into~~address a575 ~~Securities~~Pharr ~~Purchase~~Rd, ~~Agreement~~NE ~~and 8% Convertible Redeemable Promissory Note with Eagle Equities~~#53191, ~~LLC (“Eagle Equities”) for $33~~Atlanta,~~500~~ ~~(“Convertible Promissory~~GA ~~Note”)~~30355-6000. The ~~Convertible~~telephone ~~Promissory~~number ~~Note~~ is ~~due June 21, 2020 and will not be eligible for conversion to free trading~~ ~~shares until six~~ (6404) months after the issuance of the Convertible Promissory Note unless such shares are covered by a resale registration statement. The principal and accrued interest under the Convertible Promissory Note will be convertible into shares of common stock of the Company at a 50% discount to the lowest trading price during the previous 20 trading days prior to the applicable conversion date. The Company will provide and maintain a transfer agent reserve of equal to 4x the discount value of the Convertible Promissory Note. If the Company fails to maintain the share reserve at the 4x discount of the note 60 days after the issuance of the note, the conversion discount shall be increased by 10%. During the first 30 days after funding, the Convertible Promissory Note may be prepaid (in whole or in part) at 125% of the face amount plus any accrued interest. This shall increase by 5% every 30 days for the next 150 days. In no event, however, may the Convertible Promissory Note be prepaid after the six919-~~month anniversary~~4838.

~~Item 2.03 Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant~~SIGNATURES

~~The~~Pursuant ~~disclosures~~to ~~under~~the ~~Item~~requirements ~~1.01~~of the Securities Exchange Act of 1934, the registrant has duly caused this ~~Current~~report ~~Report~~to be signed on ~~Form~~its ~~8-K~~behalf by the undersigned hereunto duly authorized.

~~Item~~Medical Innovation ~~3.02~~Holdings, ~~Unregistered Sales of Equity Securities~~Inc.

~~The information set forth in Item 1.01 is incorporated by reference into this Item 3.02.~~By:

~~ITEM~~/s/ Redgie ~~9.01 FINANCIAL STATEMENTS AND EXHIBITS~~Green

Exhibit No.		Exhibits
10.1		Securities Purchase Agreement
10.2		Convertible Redeemable Promissory Note

____________________

1Redgie Green

~~SIGNATURES~~Title: Interim CEO

~~Pursuant~~Date: toSeptember ~~the requirements of the Securities Exchange Act of 1934~~10, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2019

Medical Innovation Holdings, Inc.

By:

/s/ Redgie Green

____________________

Redgie Green

Title: Interim CEO

Date: July 9, 2019

Filing Compare · MEDICAL INNOVATION HOLDINGS, INC.